XML 17 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:    
Net loss $ (62,746) $ (984)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,219 1,106
Reserve for excess and obsolete inventory 23,108 713
Change in fair value of preferred stock warrant and contingent shares liability (152) (1,109)
Change in fair value of derivative liability   (12,247)
Non-cash interest expense 8,941 5,473
Stock-based compensation 7,721 3,808
Change in allowance for credit losses (1,684) 3,870
Loss on debt extinguishment   171
Non-cash lease expense 1,122 996
Accretion of interest on marketable securities (354) (508)
Loss on disposal of property and equipment   17
Changes in operating assets and liabilities:    
Accounts receivable 570 5,201
Inventory 16,296 (37,199)
Prepaid expenses and other assets 1,658 (1,293)
Accounts payable (6,625) (8,577)
Accrued expenses and other liabilities (793) 3,383
Deferred revenue 368 (321)
Warranty liability 166 1,281
Operating lease liabilities (1,169) (1,003)
Net cash used in operating activities (12,354) (37,222)
Cash flows from investing activities:    
Purchase of marketable securities (10,976) (53,483)
Acquisition of fSight   (16)
Purchase of intangible assets   (450)
Purchase of property and equipment (1,286) (2,114)
Sales and maturities of marketable securities 32,018 25,149
Net cash provided by (used in) investing activities 19,756 (30,914)
Cash flows from financing activities:    
Proceeds from Convertible Promissory Note   50,000
Repayment of Series 2022-1 Notes   (20,833)
Payment of financing costs   (358)
Proceeds from Business Combination   2,238
Proceeds from exercise of stock options 272 215
Payment of tax withholdings on stock options (122) (91)
Payment of offering costs related to at-the-market offering (227)  
Proceeds from at-the-market offering 16  
Proceeds from common stock warrant redemption, net of issuance costs and payments to warrant holders of non-redeemed warrants   3,653
Net cash (used in) provided by financing activities (61) 34,824
Net increase (decrease) in cash 7,341 (33,312)
Cash and cash equivalents at beginning of period 4,405 37,717
Cash and cash equivalents at end of period 11,746 4,405
Supplemental disclosure of cash flow information:    
Cash paid for interest 2,510 1,418
Cash paid for income taxes 575 95
Supplemental schedule of non-cash investing and financing activities:    
Net assets acquired from Roth CH Acquisition IV Co.   573
Operating lease right of use assets obtained in exchange for operating lease liabilities 195 2,247
Property and equipment in accounts payable   693
Non-cash consideration paid for fSight acquisition 375 10,974
Contingent shares liability from fSight acquisition 0 2,167
Unrealized gain (loss) resulting from change in fair value of marketable securities $ 61 (59)
Fair value of derivative note liability at issuance   23,525
Convertible preferred stock dividends (Note 3)   12,581
Dividends on Series D and Series E convertible preferred stock   12,581
Reclassification of deferred issuance costs to additional paid in capital   2,221
Conversion of convertible preferred stock into common stock in connection with the Business Combination (Note 3)   87,140
Issuance of preferred stock upon exercise of preferred warrants   2,008
Reclassification of convertible note derivative liability to equity   $ 11,278